Sandra Carson - 08 Jun 2023 Form 4 Insider Report for AGILE THERAPEUTICS INC

Role
Director
Signature
/s/ Geoffrey P. Gilmore, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
08 Jun 2023
Net transactions value
$0
Form type
4
Filing time
09 Jun 2023, 17:09:28 UTC
Previous filing
10 Jun 2022
Next filing
26 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGRX Common Stock Award $0 +935 +2397% $0.000000 974 08 Jun 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGRX Employee Stock Option (Right to Buy) Award $0 +1,065 $0.000000 1,065 08 Jun 2023 Common Stock 1,065 $3.58 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units that were granted on June 8, 2023, which will vest and be settled in common stock on June 8, 2024, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.
F2 On April 10, 2023 the Issuer completed a one-for-fifty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split.
F3 This option was granted on June 8, 2023 and vests in full on June 8, 2024, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.